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ABSTRACT

AUTOLOGOUS FIBRINOGEN PURIFICATION AND
CONCENTRATION FOR USE IN
FIBRIN SEALANT

Steven M. Alston, Jr.
Department of Chemical Engineering
Doctor of Philosophy

Fibrinogen concentrates are used widely as a sealant during and after surgery to
reduce blood loss. Commercially available fibrin sealants are made from pooled human
blood, which carries the risk of blood-borne diseases, and are expensive. These concerns
have brought to focus the need for autologous fibrinogen concentrates. This need has
been addressed by utilizing a unique approach in which fibrinogen is precipitated from
plasma with protamine.
The physical properties of fibrin sealant prepared from fibrinogen precipitated
with protamine were evaluated. The optimal precipitation conditions included a plasma
protamine concentration of 10 mg/mL at room temperature. Under these conditions 96%
± 4% of the fibrinogen present in the plasma was precipitated and 98% ± 0.9% of the

precipitated fibrinogen was clottable. In addition, it was shown that almost 50% of the
factor XIII in the plasma was also precipitated along with the fibrinogen.
The tensile and adhesion strengths and kinetics of fibrin sealant prepared from
protamine-fibrinogen concentrate were evaluated. Tensile strength and adhesion strength
both increased with increasing fibrinogen concentration. Addition of calcium chloride
significantly increased the tensile and adhesion strengths. The addition of aprotinin and
ε-aminocaproic acid (used to inhibit natural fibrinolysis) to the fibrinogen concentrate
was shown to have no effect on the mechanical properties of the sealant. Kinetic
experiments showed that the clotting time decreased as the thrombin and fibrinogen
concentrations were increased.
A rat model with controlled renal incisions was employed to evaluate the
hemostatic efficacy of the fibrin sealant made from the protamine-fibrinogen concentrate.
The fibrin sealant significantly reduced the blood loss and bleeding time when compared
with controls (no sealant, plasma, and a commercial product). The sealant also
significantly reduced blood loss and bleeding time in rats that were anticoagulated with
heparin.
A mathematical model based on tensile strength and adhesion strength was
developed to predict the bleeding time in the animal wound. Model predictions showed
that the ability of the fibrin sealant to reduce bleeding time, and therefore blood loss, was
limited by the adhesion strength.
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CHAPTER 1: INTRODUCTION

1.1

Reducing Blood Loss During Surgery

A common method for reducing blood loss during/after surgery is to mimic the
last step of the physiological coagulation mechanism through the use of fibrin sealant
(also called fibrin glue). The sealant, formed by mixing a concentrated solution of
fibrinogen with thrombin and Ca2+ to produce fibrin, is applied to bleeding wounds and
suture lines to stop bleeding within minutes [1].

1.2

Preparation of Fibrinogen Concentrate

Conventionally, fibrinogen concentrates are either prepared from a
cryoprecipitated concentrate of fibrinogen from blood banks or an autologous plasma (i.e.
from the patient’s own blood). However, the blood-bank derived cryoprecipitates are
extracted from homologous (i.e. from other humans) blood and therefore carry the risk of
transmitting blood-borne pathogens (i.e. hepatitis, HIV). The risk is eliminated by
deriving fibrinogen from autologous plasma, but the relatively low concentration of
fibrinogen in plasma (3 mg/mL) results in a weak sealant [2].
Commercial fibrinogen preparations are available but their use is limited due to
high cost. The Food and Drug Administration recently (1998) approved the use of
1

Tisseel VH (Baxter Healthcare Corp.,Westlake Village, CA) for use in the United States.
In this product, the fibrinogen is isolated from pooled human blood, but efforts have been
made to reduce the risk of HIV and other viral contaminants by heat inactivation or
solvent/detergent extraction. However, it is well recognized that the risk of viral
contamination cannot be fully eliminated from any preparation obtained from blood
collected from multiple donors. Further, the preparation of fibrinogen concentrates is a
complex, time-consuming process. More recently, methods have been developed to
prepare concentrated fibrinogen from autologous blood in the operating room, but the
methods require complex procedures and equipment that would be difficult to extend to
emergency situations.

1.3

Goals of this Dissertation

The specific goals of this dissertation were to: 1) develop a quick, inexpensive
process to harvest concentrated fibrinogen from autologous patient blood for use as a
fibrin sealant; 2) evaluate the in-vitro mechanical properties of the fibrinogen
concentrate; and 3) evaluate the efficacy of the fibrinogen concentrate in an in-vivo
animal wound model.

2

CHAPTER 2: BACKGROUND

2.1

Blood and Coagulation

The blood volume of an average adult is about 5 liters, consisting of formed
elements (~40 vol%) and plasma (~60 vol%) [3]. The formed elements in blood include
erythrocytes (red blood cells), leukocytes (white blood cells), and thrombocytes
(platelets). Blood plasma is a dilute (0.15 N) electrolyte solution containing inorganic
ions, numerous proteins, and other molecules [4].
The body has inherent mechanisms to limit blood loss as a lack of blood flow
rapidly leads to cell, tissue, and organ death. Hemostasis is the arrest of bleeding, and
coagulation plays an important role in hemostasis by helping to minimize blood loss from
the body [3]. Coagulation occurs when appropriate stimuli activate a group of
procoagulant plasma proteins, which activate each other in an enzymatic cascade to
eventually form a viscous gel (Figure 2.1). The intrinsic pathway (activated by
components wholly contained within the vasculature [3]) and/or the extrinsic pathway
(activated by tissue injury) lead to activation of the common pathway and the formation
of a stabilized fibrin clot.
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Figure 2.1: A simplified version of the coagulation cascade.

2.2

The Role of Fibrinogen

Fibrinogen is a soluble blood protein that comprises 3 mg/mL of plasma [5]. It is
converted into an insoluble fibrin network in the presence of thrombin as part of the
intrinsic and extrinsic coagulation cascades. Thrombin cleaves fibrinopeptides A and B
from the fibrinogen molecule to form fibrin monomer, which polymerizes to form a weak
fibrin clot. Factor XIII, activated by thrombin and Ca2+, catalyzes crosslinking of the
fibrin molecules, resulting in a stable clot [6].

4

2.3

Fibrin as a Tissue Sealant

While the first documented use of fibrin as a tissue adhesive dates back to 1909,
Cronkite and associates are credited as being the first to combine fibrinogen and
thrombin to form an adhesive gel for attaching skin grafts during World War II [7].
Matras [8] is recognized for having used a concentrated fibrinogen solution to form a
viscous gel for peripheral nerve repair, thus bringing fibrin glue on the stage as an
effective tissue sealant. These early forms of fibrin sealant lacked adequate adhesive
strength due to their low fibrinogen concentrations. It wasn’t until the 1970s that plasma
fractionation methods emerged allowing the production of more concentrated protein
solutions [9]. However, the Food and Drug Administration (FDA) prohibited the use of
commercial fibrin sealants in 1978 because of the high risk of hepatitis transmission [2].
During this time fibrin sealants continued to be used in Europe, and today several
commercial preparations are available. The FDA recently (1998) approved the use of
Tisseel VH (Baxter-Immuno, Vienna, Austria) for commercial use in the United States.
Other commercial sealants are currently in clinical trails for FDA approval.
Considering the critical role that fibrin plays in hemostasis, and possibly in wound
repair, it has been recognized for decades as an attractive primary ingredient upon which
to base the development of an effective tissue sealant. The major limitations in
developing a fibrin-based sealant that can be widely utilized have been the risk of bloodborne infections, and the costs associated with harvesting concentrated protein solutions.
Despite these limitations, fibrin sealant has been used successfully in almost every field
of surgery including cardiothoracic [10], neurologic [11], ophthalmologic [12],
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orthopedic [13, 14], vascular [15], and other fields [16, 17]. Other potential applications
contemplated for utilizing fibrin-based sealant include delivery of antibiotics at the
wound site to ward infection [18], delivery of growth factors or other additives to
improve wound healing [19], and delivery of chemotherapeutic agents to treat
malignancies [20].

2.4

Composition of Fibrin Sealant

The main components in a fibrin sealant are fibrinogen and thrombin, although
other constituents such as factor XIII and antifibrinolytic agents may also be present [21].
The performance of a fibrin sealant is determined by the individual components present
in the final product.
Fibrinogen is the main structural component in fibrin sealant and can range in
concentration from 3 mg/mL to 130 mg/mL [21]. It has been shown that the mechanical
strength and clotting time of fibrin sealant are directly related to the fibrinogen
concentration [9, 22]. Increasing the fibrinogen concentration increases the tensile and
adhesion strengths and decreases the clotting time of fibrin sealant. It is desirable to have
a fibrinogen concentration of 60 mg/mL or greater in order to provide complete
hemostasis [23].
The second major component of fibrin sealant is thrombin, which is present at a
concentration of 4-1000 U/mL [21, 24]. The main function of thrombin is to convert
fibrinogen into fibrin. Because of this, the clotting time is determined by the
concentrations of both fibrinogen and thrombin. Products that have a low thrombin
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concentration will clot at a much slower rate than those with high concentrations of
thrombin [21].
Factor XIII is activated by thrombin, in the presence of calcium, and is
responsible for cross-linking fibrin. The concentration of factor XIII in fibrin sealants
ranges from 0 to 80 U/mL [25]. The presence of factor XIII has been shown to
significantly increase the tensile and adhesion strengths of fibrin sealant and improve the
in-vivo hemostatic efficacy [26-28]. The cross-linking of fibrin stabilizes the clot and
makes it less susceptible to fibrinolytic breakdown. Factor XIII has also been shown to
crosslink adhesive proteins, such as fibronectin [29], thrombospondin [30], and von
Willebrand factor [31] to fibrin, increasing the adhesion strength.
Some fibrin sealants may have a fibrinolytic inhibitor, such as aprotinin or εaminocaproic acid, added to them to increase clot stability [32]. It has been shown that
clots formed from fibrin sealant containing aprotinin or ε-aminocaproic acid exhibit
decreased lysis [33]. However, it has also been shown that fibrinolytic inhibitors are not
necessary in fibrin sealant and may negatively affect tissue remodeling [34].

2.5

Isolation of Fibrinogen

Since the main component of fibrin sealant is fibrinogen, many different methods
have been developed to harvest fibrinogen for this purpose.
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2.5.1

Cryoprecipitation
The ‘gold standard’ for isolating fibrinogen from human blood is

cryoprecipitation, which utilizes the low fibrinogen solubility at cold temperatures.
Plasma is frozen at –80 oC for at least 12 hours, thawed for several hours at 4 oC,
followed by centrifugation. The supernatant is then decanted leaving a yellowish
precipitate of fibrinogen, which is then reconstituted in a small amount of supernatant
plasma. Fibrinogen concentrations obtained from cryoprecipitation range from 20-40
mg/mL [35-37]. Because cryoprecipitation requires no chemical manipulation, this
approach has been used widely in blood banking to provide a crude clotting factor
concentrate to manage hemostatically deficient patients. While cryoprecipitation steps
are utilized for large-scale preparation of fibrinogen from pooled blood, this approach is
not practical for the harvesting of fibrinogen from small volumes of blood on short
notice. Cryoprecipitate also carries the potential risk of virus transmission because it is
prepared from pooled donor blood.

2.5.2

Ultrafiltration
Ultrafiltration combines the use of pressure and semi-permeable membranes to

separate molecular species by size, shape, and/or charge. This technique has been used to
concentrate plasma and has been suggested for use in preparing fibrin sealant. Interpore
Cross, Inc. (Irvine, CA) has developed a plasma concentrator based on ultrafiltration [38],
in which platelet-rich plasma is delivered to an ultrafiltration chamber with a molecular
weight cutoff of 30,000 Daltons. The concentrated plasma is collected out of the bottom
of the chamber and can be used to prepare fibrin sealant. Harvesting fibrinogen by this
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approach yields a final fibrinogen concentration of approximately 6 mg/mL [39]. In
addition, a significant portion of the fibrinogen is denatured in the process, rendering
only 70% of the collected protein clottable [39].

2.5.3

Centrifugation
The Cell Saver is a centrifugal blood concentrator that separates and concentrates

red blood cells, platelets, and plasma proteins by removing plasma from whole blood [4042]. The physical separation of blood components is based on the differences in density
and particle size [43]. Fibrinogen harvested from the cell saver has been investigated for
use in fibrin sealant [44]. The efficacy of fibrin sealant made from concentrated
fibrinogen collected from the cell saver was compared to the efficacy of a commercial
fibrin sealant. The commercial fibrin sealant performed significantly better than the cell
saver fibrin sealant due to the significantly higher fibrinogen concentration in the
commercial sealant.

2.5.4

Chemical Precipitation
Methods have also been proposed to precipitate fibrinogen using chemical agents

such as ethanol, polyethylene glycol (PEG), or ammonium sulfate [45-47]. Chemical
precipitation methods present many advantages over cryoprecipitation. First, the entire
preparation requires only 90 minutes, eliminating the need for pre-surgical patients to
donate blood 1-2 days prior to surgery. The fibrinogen yield with chemical precipitation
is greater than cryoprecipitation, thereby reducing the amount of plasma required. These
factors make it possible to use autologous patient blood for preparing the fibrinogen. The
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use of autologous blood eliminates the risk of blood-borne virus transmission. The
concentration of fibrinogen prepared from chemical precipitation ranges from 30 to 50
mg/mL [2].
However, chemical precipitation with these agents does have some disadvantages.
For example, ethanol precipitation leaves elevated levels of ethanol in the fibrinogen
concentrate that can result in premature clotting of the fibrinogen [2]. Factor XIII, which
is necessary for stabilizing the clot, has reduced activity in the presence of ethanol,
resulting in reduced clot tensile strength [48]. Ammonium sulfate precipitates 55% of the
fibrinogen and a large amount of albumin that can interfere with clotting [49]. PEG
precipitation requires that prothrombin be absorbed with BaSO4 and MgSO4 before
addition of PEG to precipitate fibrinogen [50]. In addition, PEG may modify the
fibrinogen and yield it unclottable [51].
Protamine has also been shown to precipitate fibrinogen [52-54]. Protamine is a
small (MW 5 kDa), positively charged protein harvested from fish sperm. It is routinely
used to restore clotting function in patients that have been anticoagulated with heparin.
Protamine has been shown to precipitate up to 100% of the fibrinogen in the plasma [54].
The precipitation step is rapid, and recoveries have been reported of up to 100% of the
fibrinogen [54].
The Vivostat system is a medical device that utilizes chemical precipitation to
prepare patient-derived fibrinogen concentrate [55]. 120 mL of the patient’s blood is
placed into the processor, and the automated processing is started to obtain platelet-poor
plasma. The plasma is reacted with biotin-batroxobin for 10 minutes at 37 oC which
results in the formation of an acid soluble fibrin I polymer. The polymer is removed with
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centrifugation and dissolved in a sodium acetate buffer (pH 4). The solution is filtered to
isolate fibrin I and is loaded into a syringe. Another syringe is prepared containing a
carbonate/bicarbonate buffer (pH 10). The two syringes are applied simultaneously
resulting in the formation of a fibrin clot. The Vivostat system takes approximately 30
minutes to process the patient’s blood and to concentrate fibrin I.

2.5.5

Chromatographic Methods
Fibrinogen has been shown to bind to several different immobilized ligands via

affinity and ion exchange chromatography. All of these approaches require plasma to be
passed through a column containing the ligand bound to a matrix. The fibrinogen in the
plasma binds to the ligand and is then eluted from the gel [5, 56]. These approaches have
been employed to study molecular interactions of fibrinogen with other blood
components as well as the function of fibrinogen, however, these approaches have not
been proven conducive for preparation of fibrinogen concentrate.

2.5.5.1 Fibrin Monomer Matrix
The high affinity of fibrinogen for fibrin monomer has been employed for
purifying fibrinogen [57-59]. Fibrin monomer immobilized on a chromatography gel
matrix can be utilized to bind fibrinogen in plasma. The fibrinogen can then be harvested
from the fibrin monomer.
Experiments showed that 90% of the applied fibrinogen bound to the fibrin
monomer gel matrix. 60 to 95% of the bound fibrinogen was eluted with a buffer of 0.05
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M Tris-H3PO4, 2.0 M NaBr, and 0.005 M EDTA at pH 5.3. Clotting assays showed that
85 to 100% of the recovered fibrinogen was clottable.
Fibrinogen is adsorbed from plasma onto immobilized fibrin monomer with high
specificity. The eluted fibrinogen appears not to be altered as shown from the
clottability. However, fibrinogen is denatured in media with a pH lower than 5.5 [60]. In
order to recover functional fibrinogen, it is necessary to keep the contact time with the
buffer as short as possible. This technique has also been shown to remove fibrin
degradation products (FDP) from plasma [57].

2.5.5.2 Heparin Matrix
Heparin immobilized on Sepharose was shown to bind fibrinogen, and binding
assays showed that approximately 30 minutes were required to reach a maximal binding
of 125I-labeled fibrinogen [61]. Labeled fibrinogen binding was completely inhibited in
the presence of NaCl at concentrations of 0.5 M and greater. At a concentration of 50
mg/mL free heparin, the binding was completely inhibited. More than 80% of the bound
labeled fibrinogen was displaced in the presence of 200-fold excess of unlabeled
fibrinogen.
Heparin immobilized on Sepharose is also used to remove and purify other blood
proteins. Currently this technique is used commercially to produce concentrates of antithrombin III, an important coagulation inhibitor[62]. Anti-thrombin III is easily removed
from heparin-Sepharose by gradient elution with NaCl [5].
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2.5.5.3 Protamine Matrix
Fibrinogen was also shown to bind to protamine immobilized on Sepharose beads
(protamine-Sepharose) [63, 64]. The fibrinogen formed a non-specific ionic bond with
the immobilized protamine. Binding experiments in columns showed that 100 % of the
applied fibrinogen adsorbed to the protamine-Sepharose within 10 minutes. Elution of
65-80% of the bound fibrinogen was achieved with a buffer of 0.05 M tris/HCl, 0.005 M
Na2EDTA, and 0.005 M epsilon-amino caproic acid (εACA) at a pH of 4.5. Clotting
assays further showed that approximately 6.5 mg of pH 4.5-elutable fibrinogen adsorbed
to 1 mL of protamine-Sepharose.
In the work reported here, preliminary attempts were made to purify and
concentrate fibrinogen using protamine-Sepharose chromatography. Approximately 90%
of the fibrinogen applied to a column packed with protamine-Sepharose bound to the gel.
However, since 45% of the bound fibrinogen could be eluted from the gel, this approach
was not used.

2.6

Fibrin Sealant Preparations

2.6.1

Commercial Sealants
The only FDA-approved, commercially-available fibrin sealant in the United

States is Tisseel VH. The Tisseel VH kit is supplied with four separate vials containing
freeze-dried human fibrinogen (75-115 mg/mL), freeze-dried human thrombin (500
IU/mL), bovine aprotinin solution (3000 KIU/mL), and calcium chloride solution (40
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mmol/L) [23]. Also included with the kit are two identical syringes and a Duploject
applicator (Figure 2.2).

Figure 2.2: Duploject applicator[65].

The fibrinogen is reconstituted with the aprotinin solution while the thrombin is
reconstituted with the calcium chloride. The fibrinogen/aprotinin is loaded into one
syringe and the thrombin/calcium chloride into the other. The syringes are loaded into
the Duploject applicator that has a common plunger to insure that the two components are
delivered with equal volume. The solutions then travel through a common joining piece
where they are mixed uniformly before being expelled through a blunt needle onto the
wound site [23].
Commercial preparations have been used in Europe for over 20 years and many
are available for use. Table 2.1 outlines some of the available sealants and their
compositions [1, 24, 25].
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Table 2.1: Composition of commercially-available fibrin sealants in Europe.

Beriplast
(Aventis Behring)
Biocol
(LFB)
Bolheal
(Kaketsuken)
Hemaseel APR
(Haemacure)
Quixil
(Omrix)
Tissucol
(Baxter-Immuno)
VIGuard
(Vitex)

Fibrinogen
(mg/mL)

Thrombin
(U/mL)

Factor XIII
(U/mL)

65-115

400-600

40-80

127

558

11

80

250

57

75-115

500

None

60-100

1000

None

70-110

500

10-50

50-95

200

3-5

Fibrinolytic
Inhibitor
Aprotinin
(3000 KIU/mL)
Aprotinin
(3000 KIU/mL)
Aprotinin
(1000 KIU/mL)
Aprotinin
(3000 KIU/mL)
Tranexamic acid
(95 mg/mL)
Aprotinin
(3000 KIU/mL)
None

Use of commercial fibrin sealant is often prohibited by cost and availability. The
cost of Tisseel is $132 per mL of fibrinogen concentrate [23]. If a significant volume of
sealant is needed, the use of Tisseel can quickly become cost prohibitive. Commercial
sealants are available only if stocked in plentiful quantities, which occasionally may not
be the case. The relevance of the latter requirement is illustrated in a recent medical log
in which a surgeon related that “Fibrin glue was applied (home-made, since the only
Tisseel carried at big hospital (sic) was in the 1cc amounts).” [66].

2.6.2

Home-Made Sealants
The alternative to using a commercial fibrin sealant is to use a home-made fibrin

sealant. There are multiple recipes for preparing home-made fibrin sealant, all of which
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consist of mixing plasma or cryoprecipitate with bovine thrombin [23, 67-69]. The
thrombin component is mixed with calcium chloride and loaded into a syringe. The
fibrinogen component is loaded into a second syringe. In most applications the contents
of the two syringes are applied simultaneously [69]. In other methods, the two syringes
are attached to a multiple lumen catheter and the two syringes are squirted
simultaneously, which mixes the two solutions and dispenses the sealant onto the wound
site [67]. Because home-made sealants are made from plasma or cryoprecipitate, they
have much lower fibrinogen concentrations than found in commercial sealants.

2.6.3

Risk of Virus Transmission

The safety of commercial fibrin sealants is ensured by four complementary
approaches: (1) careful selection of blood donors; (2) extensive testing of donated blood
for viral markers; (3) rigorous removal of infectious human viruses by a range of protein
purification methods; and (4) the use of virus-inactivation methods during the
manufacturing process [70]. Virus inactivation methods used are solvent/detergent
treatment and vapor heat treatment [1, 70]. These techniques are effective against viruses
with a lipid envelope, such as HIV, hepatitis B and C, but are less effective against
viruses without a lipid envelope, such as hepatitis A and parvovirus B19 [71]. Tisseel
VH has been used in over 8 million procedures worldwide without any confirmed cases
of HIV; hepatitis A, B, or C; or Creutzfeldt-Jakob Disease to date [72]. There have been
reported cases of parvovirus B19 transmission from commercial sealants [73, 74], which
has been remedied by implementing more rigorous testing of donated blood.
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When cost or availability prohibits the use of commercial sealants, home-made
sealants are used. Blood donated at a blood bank undergoes less rigorous testing for viral
markers than plasma used in commercial fibrin sealants. Furthermore, blood-bank blood
does not undergo protein purification and virus-inactivation methods used in commercial
fibrin sealants and is associated with a higher risk of viral transmission [70].

2.7

In-Vitro Evaluations

2.7.1

Tensile Strength
The clinical performance of a fibrin sealant is influenced by its physical properties

such as tensile strength and adhesion strength [75]. Many factors including fibrinogen
concentration, calcium concentration, the presence of other plasma proteins, ionic
strength, and temperature affect the rate and extent of fibrin polymerization and,
ultimately, the mechanical properties [25]. The optimization of these properties is
important to both the manufacturers and surgeons.
Tensile strength is mainly a function of fibrinogen concentration and is frequently
used as an indicator of quality [76]. A number of different models have been proposed to
evaluate the tensile strength of fibrin sealant.
Rubenstein [77] reported forming cylindrical clots in siliconized glass tubes for
testing tensile strength. The clots were cured for 30 minutes and removed from the tubes.
The two ends of the cylindrical clots were placed in clamps, and a cup was attached to the
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bottom clamp. Weights were added to the cup until the clot ruptured. The tensile
strength was calculated from the amount of weight required to rupture the clot.
Nowotny, et al. [78] and Velada et al. [79] molded clots for tensile strength
testing. Clots were formed by injecting fibrinogen and thrombin into a mold. The clots
were removed from the mold and placed in an Instron machine. The tensile strength was
determined by pulling apart the clots and measuring the force required to rupture the clot.

2.7.2

Adhesion Strength
Adhesion strength is also a function of fibrinogen concentration and is a good

indicator of how a fibrin sealant will perform in sealing a wound. Many different
methods have been proposed for testing the adhesion strength of a fibrin sealant. Some
of these methods consist of using silastic [76] or other artifical materials [46]. These
models have little clinical relevance as they do not measure the adhesion of fibrin sealant
to tissue.
Silver, et al. [47] have measured the adhesion strength of fibrin sealant using
collagen. Collagen films were made and cut into two equal halves. The two halves were
overlapped by 1 cm and fibrin sealant was applied between the overlapping pieces. The
films were cut into 1 cm wide strips and put into an Instron machine. Adhesion strength
was calculated as the strength required to cause the overlapping joints to fail.
Dickneite, et al.[25], Kjaergard, et al.[75], and Laitakari, et al. [80] have all
reported measuring the adhesion strength with animal or human tissue. Fresh rat skin,
porcine skin, human dura, or human vascular tissue were affixed to small blocks with
sutures or pins. Fibrin sealant was applied between two sample blocks and allowed to
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cure. The adhesion strength was measured as the maximum force required to pull apart
the sample blocks.

2.8

Animal Model Evaluation

Although the in-vitro mechanical properties of a fibrin sealant are good indicators
of quality and performance, a better indicator is how well the sealant stops bleeding in an
in-vivo animal wound model. Many different types of animal models have been
employed to evaluate fibrin sealant.
A kidney excision model has been reported for evaluating fibrin sealant in rats
and rabbits [25-27, 81]. The animal was anesthetized and the abdomen was opened and
the renal artery was clamped off to stop blood flow to the kidney. A piece of the kidney,
generally 20%, was excised and any blood loss from the wound was absorbed with gauze.
Fibrin sealant was applied to the wound area and allowed to cure for a predetermined
amount of time. The artery clamps were removed and blood flow to the organ was
restored. The fibrin sealant performance was evaluated by blood loss which was
measured by soaking up blood with pieces of pre-weighed gauze. This model does not
evaluate how well a fibrin sealant performs when applied to a bleeding wound, because
blood flow to the kidney was stopped before the sealant was applied.
An aorta/artery bleeding model has been used to evaluate the efficacy of fibrin
sealant in rabbits and dogs [82-84]. The animal was anesthetized and the abdomen was
opened. The aorta or other artery was clamped proximally and distally to occlude blood
flow and was severed in the middle. The vessel was sutured back together with sutures
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placed 0.3 cm apart. Fibrin sealant was applied and allowed to cure for a predetermined
amount of time. Blood flow was restored by removing the clamps and blood loss was
measured by soaking up blood with pieces of pre-weighed gauze. As in the kidney
excision model, this model provides a good evaluation of how much pressure a fibrin
sealant can withstand, but does not address how well a fibrin sealant performs when
applied to a bleeding wound.
A liver incision model has been proposed as an evaluation of fibrin sealant
performance in rats [34, 44]. The animal was anesthetized and the abdomen was opened,
exposing the liver. A 1 to 3 cm long incision was made in the liver, and fibrin sealant
was applied. Blood loss was measured by soaking up blood with pieces of pre-weighed
gauze. This model provides a good evaluation of how well a fibrin sealant performs
when applied to a bleeding wound. Because the average blood pressures are much lower
in the kidney[3], this model is not a good measure of how much pressure a fibrin sealant
can withstand. Extending this model to the kidney would evaluate how well a fibrin
sealant performs when applied to a higher pressure bleeding wound.

2.9

What is Missing?

Fibrin sealants have been shown to be very effective in reducing blood loss during
and after surgery. Purifying and concentrating fibrinogen remains the limiting step in the
production of fibrin sealant. Conventional methods currently used, such as
cryoprecipitation and chemical precipitation, present many drawbacks such as long
processing time, large blood volume, and the use of chemicals that can be toxic to the
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body. Commercial sealants are available, but carry the burden of high cost and
availability. Home-made sealants suffer from a higher risk of virus transmission and low
fibrinogen concentrations.
From the discussion it is obvious that a method to rapidly and inexpensively
purify and concentrate autologous fibrinogen is needed. Protamine has been shown to
precipitate up to 100 % of fibrinogen from plasma. Because of this, protamine was
considered an excellent candidate for use in preparing autologous fibrinogen. This
dissertation reports analysis of fibrinogen concentrate prepared by protamine
precipitation based on in-vitro mechanical properties and hemostatic efficacy in an
animal model.
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CHAPTER 3: OBJECTIVES

The overall goal of the research was to evaluate fibrinogen concentrate prepared
from protamine precipitation for use in a fibrin sealant. This overall goal was divided
into the following 5 objectives:

1.

Develop a method to rapidly harvest and concentrate fibrinogen with protamine
and evaluate the concentrate for fibrinogen and factor XIII content and
functionality.

2.

Develop in-vitro models to evaluate the tensile strength and adhesion strength of a
fibrin sealant. Evaluate the quality of the precipitated fibrinogen by evaluating
the tensile strength and adhesion strength using these models.

3.

Evaluate the kinetic behavior of the precipitated fibrinogen.

4.

Determine the hemostatic efficacy of the protamine-fibrinogen concentrate in an
animal model.

5.

Mathematically model the performance of the fibrin sealant in an animal model to
optimize the fibrin sealant operating conditions.
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CHAPTER 4: PREPARATION AND EVALUATION OF FIBRINOGEN
CONCENTRATE

4.1

Experimental Methods

Blood was collected from healthy adult human donors by venapuncture into
sodium citrate (Sigma Chemical Co., St. Louis, MO; final concentration 0.38 g/100mL)
and centrifuged for 30 minutes at 1200 g to obtain platelet-poor plasma (PPP). The
plasma was used immediately or stored at -80 oC.
Fibrinogen was precipitated from pooled human plasma (minimum of eight
donors) by addition of protamine sulfate (Sigma Chemical Co., stock concentration 40
mg/mL). Following the addition of protamine, the plasma was centrifuged at 1000 g for
5 min to sediment the precipitate. The plasma was then decanted, and the remaining
precipitate was dissolved in the same volume (as the initial plasma) of 0.2 M sodium
citrate (37oC, pH 7.4). Fibrinogen concentrations in the starting plasma and concentrate
were evaluated with an enzyme-linked immunosorbent assay (ELISA) (AssayPro LLC,
Brooklyn, NY). Samples were added to wells pre-coated with an antibody specific for
fibrinogen and competed with a biotinylated fibrinogen for antibody binding sites. The
sample fibrinogen was sandwiched between the capture antibody and a streptavidinperoxidase conjugate. All unbound material was washed away and a peroxidase enzyme
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substrate was added resulting in color change. The color development was stopped and
the intensity of the color was measured with a Dynex MRX microplate reader (Dynex
Technologies, Chantilly, Virginia). Sample fibrinogen concentrations were calculated
from a standard curve. The percentage of fibrinogen harvested was taken to be the ratio
of fibrinogen in the concentrate to the fibrinogen in the initial plasma sample.

4.2

Effect of Protamine Concentration

The final concentrations of protamine in the plasma were varied from 9 mg/mL to
12 mg/mL as guided by the literature [53, 54] to obtain the optimal yield of fibrinogen.
At a plasma protamine concentration of 10 mg/mL, 96% ± 4% (n=4) of the fibrinogen in
the plasma was found in the concentrate (Figure 4.1). The molar concentration of
protamine in the plasma was 2000 μM compared to the molar concentration of fibrinogen
of 8.8 μM. Plasma concentrations of protamine below 10 mg/mL did not precipitate all
of the fibrinogen in the plasma. Plasma concentrations above 10 mg/mL resulted in a
precipitate comprised of very tiny aggregates that would not completely dissolve back
into solution.
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Figure 4.1: The amount of fibrinogen precipitated as a function of the final protamine concentration
in the plasma (n=4). The results are displayed as the ratio of fibrinogen in the concentrate to
fibrinogen in the original plasma. At a protamine concentration of 10 mg/mL ~96% of the
fibrinogen in the original plasma precipitated. Data are shown as mean values ± SD.

4.3

Effect of Temperature

The temperature-dependent nature of the fibrinogen precipitation was investigated
by bringing the plasma protamine concentration to 10 mg/mL in plasma samples at 37,
22, 15, and 7 oC. At a plasma temperature of 22 oC (room temperature), 96% ± 4% (n=4)
of the fibrinogen was found in the precipitate (Figure 4.2). Plasma temperatures lower
than room temperature did not increase the yield of fibrinogen in the concentrate. At a
plasma temperature of 37 oC (body temperature), 75% ± 6% of the fibrinogen in the
plasma was found in the concentrate.
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Figure 4.2: The amount of fibrinogen precipitated as a function of temperature (n=4). The results
are displayed as the ratio of fibrinogen in the concentrate to fibrinogen in the original plasma. At
temperatures of 22oC and below, ~96% of the fibrinogen in the original plasma was precipitated.
This decreased to ~75% when the temperature was raised to 37oC. Data are shown as mean values ±
SD.

4.4

Evaluation of Factor XIII

The presence of factor XIII has been shown to significantly improve the in-vitro
and in-vivo performance of a fibrin sealant [21, 26-28]. Earlier publications have
indicated that protamine may bind to factor XIII [63, 64], suggesting that factor XIII may
also be harvested by the protamine-fibrinogen precipitation method investigated here.
The fibrinogen concentrate was evaluated for factor XIII content. Protamine was
added to room temperature plasma to a concentration of 10 mg/mL. The amount of
factor XIII in the initial plasma and in the fibrinogen concentrate was determined with
ELISA. Samples were added to wells pre-coated with an antibody specific for factor
XIII. The sample factor XIII was sandwiched between the capture antibody and a
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biotinylated polyclonal antibody specific for factor XIII, which was recognized by a
streptavidin-peroxidase conjugate. All unbound material was washed away and a
peroxidase enzyme substrate was added resulting in color change. The color
development was stopped and the intensity of the color was measured with a Dynex
MRX microplate reader. Sample factor XIII concentrations were calculated from a
standard curve. At these conditions, 47% ± 0.6% (n=4) of the factor XIII in the initial
plasma was found in the concentrate.

4.5

Clottability of Precipitated Proteins

To confirm the clottability of the recovered fibrinogen, 1 mL of fibrinogen
concentrate was mixed with 100 μL of bovine thrombin (Vital Products, Inc, Boynton
Beach, FL, 500 Units/mL) and allowed to clot. The clot was centrifuged for 2 min at
3500 g and the supernatant was drawn off. The amount of fibrinogen in the clot
supernatant and the amount of fibrinogen in the concentrate were measured with ELISA.
The fraction of clottable fibrinogen was taken to be the ratio of the difference between
the amount of fibrinogen in the concentrate and clot supernatant to the amount of
fibrinogen in the concentrate. The clottablility of the fibrinogen was found to be 98% ±
0.9% (n=4).
Factor XIII requires Ca2+ as a cofactor in order to participate in clotting [3]. To
evaluate the clottability of the harvested factor XIII, the above process was repeated with
the addition of calcium chloride (Spectrum Quality Products, Inc., Gardena, CA). The
amount of fibrinogen and factor XIII in the clot supernatant and the amount of fibrinogen
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and factor XIII in the concentrate were measured with ELISA. No change in the
clottability of the fibrinogen was observed when calcium chloride was added to the
concentrate. 30% ± 1% of the precipitated factor XIII participates in clotting (n=4).

4.6

Effect of Heparin

Fibrin sealants are routinely used in surgery that requires the patient to be
anticoagulated with heparin. The amounts and clottability of fibrinogen and factor XIII
harvested from plasma that was anticoagulated with heparin were measured. Blood was
drawn into porcine heparin (ESi Pharmaceuticals, Cherry Hill, NJ; final concentration 2
U/mL) and centrifuged for 30 minutes at 1200 g to obtain PPP. Protamine was added to a
known amount of plasma to bring the plasma concentrations to 10, 11, and 12 mg/mL.
Fibrinogen concentrate was prepared as previously described. The amounts of fibrinogen
and factor XIII in the concentrate were measured with ELISA.
The maximum yield of fibrinogen occurred at a protamine concentration of 11
mg/mL in plasma in contrast to 10 mg/mL seen when no heparin was present,
precipitating 95% ± 1% (n=4) of the fibrinogen in the plasma. At this protamine
concentration, 31% ± 3% (n=4) of the factor XIII in the plasma was found in the
concentrate. The observed increase in protamine concentration needed to maximize the
yield of harvested fibrinogen was expected because protamine binds to heparin as well as
to fibrinogen. Protamine is used to bind to and neutralize the anticoagulating effect of
heparin in patients following cardiopulmonary bypass surgery [85]. 1 mg of protamine
will neutralize 100 U of heparin. The increase in protamine concentration is required to
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bind all of the heparin along with binding the fibrinogen. There were no observed
changes in protein clottability when the heparin was present.
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CHAPTER 5: IN-VITRO MECHANICAL PROPERTIES

The clinical performance of a fibrin sealant is influenced by its physical properties
such as tensile strength and adhesion strength [75]. Many factors including fibrinogen
concentration, calcium concentration, the presence of other plasma proteins, ionic
strength, and temperature affect the rate and extent of fibrin polymerization and,
ultimately, the mechanical properties [25]. This chapter will detail the development of a
model to evaluate the tensile strength and a model to evaluate the adhesion strength and
the optimization of these properties.

5.1

Tensile Strength

5.1.1

Experimental Method
Fibrin clots for tensile strength testing were cast in a mold as shown in Figure 5.1.

Two separate dies made of plexiglass, held together with screws, formed the mold.
Removable plexiglass holders were put into both ends of the mold and sealed with Orings. Stiff sponges were used to provide an anchor for the clot to form around and were
tucked into the holders and held in place with bolts. The sample diameter was 2 mm in
the center and 6.5 mm at the ends, the length was 31 mm, and the mold had a total
volume of 1.5 mL. The samples were prepared by continuously emptying a syringe of
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fibrinogen and a syringe of thrombin into a common duct where they were mixed. The
mixture then entered the mold through the sponges until it discharged from the opposite
end. Care was taken to ensure that air bubbles weren’t formed in the clot as this would
weaken the sample. The plexiglass dies were removed after the sample had cured for 30
minutes, and the sample and holders were transferred to an Instron Model 1120 Universal
Testing Instrument (max load 500 g). Stress-strain was recorded while the sample was
strained at 100 mm/min until it ruptured. Tensile strength was taken as the maximum
stress sustained.

Figure 5.1: Mold for casting clots to test for tensile strength. Fibrinogen and thrombin were injected
into the mold as shown. The plexiglass mold was removed for tensile testing.

5.1.2

Effect of Thrombin
The effect of the amount of thrombin on tensile strength was determined by

holding the fibrinogen concentration constant and changing the amount of thrombin used.
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Samples were prepared from a 15 mg/mL fibrinogen concentrate and 75, 100, or 125 U
of bovine thrombin (final concentrations 45, 60, 75 U/mL clot). Clots were cast into the
molds and cured for 30 min. No significant differences (p=0.51) were observed between
the three different amounts of thrombin (Figure 5.2). The rest of the tensile strength
experiments were performed with a final thrombin concentration of 60 U/mL clot.
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Figure 5.2: Tensile strength as a function of final thrombin concentration in the clot (n=4).
Fibrinogen concentration was 15 mg/mL. No significant differences (p=0.51) in tensile strength were
observed at the different thrombin concentrations. Data are shown as mean values ± SD.

5.1.3

Effect of Fibrinogen Concentration
To evaluate the effect of fibrinogen concentration on tensile strength, samples

were prepared with fibrinogen concentrations of 15, 30, 45, and 60 mg/mL. Controls of
pooled plasma (3 mg/mL), pure fibrinogen (15 mg/mL), and Tisseel (average
concentration 95 mg/mL) were used. Clots were cast in the molds and cured for 30 min.
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Tensile strength was found to increase approximately linearly with increasing fibrinogen
concentration as shown in Figure 5.3.
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Figure 5.3: Tensile strength as a function of fibrinogen concentration (n=4). Controls of plasma,
pure fibrinogen, and Tisseel were used. The tensile strength increased linearly with fibrinogen
concentration. The tensile strength of plasma and Tisseel lie near the curve. The tensile strength of
pure fibrinogen was significantly greater than that of the protamine-fibrinogen (p<0.05). Data are
shown as mean values ± SD.

The tensile strength of the samples formed with plasma and Tisseel fall near the
curve with the samples formed with the protamine-fibrinogen concentrates. The tensile
strength of the 15 mg/mL pure fibrinogen sample was significantly higher than that of the
15 mg/mL protamine-fibrinogen sample (p<0.05). The major difference between these
two concentrate preparations is the precipitation with protamine.
To verify that the addition of protamine adversely affected the tensile strength,
samples were prepared from a 15 mg/mL pure fibrinogen concentrate and a 15 mg/mL
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fibrinogen concentrate prepared by protamine precipitation of pure fibrinogen (Figure
5.4). The fibrinogen concentration of each sample was measured to ensure that the
fibrinogen concentrations were the same. The tensile strength of the precipitated pure
fibrinogen was significantly lower than the pure fibrinogen (p<0.05). This was due to the
presence of protamine in the concentrate.
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Figure 5.4: Tensile strength of 15 mg/mL fibrinogen concentrates prepared from pure fibrinogen,
precipitated pure fibrinogen, and protamine-fibrinogen (n=4). Precipitation of the pure fibrinogen
concentrate significantly lowered the tensile strength (p<0.05). Data are shown as mean values ± SD.

5.1.4

Effect of Calcium
The effect of calcium on clot tensile strength was investigated by adding calcium

chloride to a 15 mg/mL solution of protamine-fibrinogen. Final concentrations of
calcium chloride in the fibrinogen concentrate were 0, 0.0036, 0.0089, 0.018, 0.035, 0.05,
0.075, and 0.1 M. Clots were cast in the molds and cured for 30 min. The concentration
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of calcium chloride in the concentrate yielding the highest tensile strength was in the
range of 0.0089 to 0.05 M (Figure 5.5).
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Figure 5.5: Tensile strength as a function of calcium chloride concentration (n=4). A fibrinogen
concentration of 15 mg/mL was used. The tensile strength reached a maximum in the range of
0.0089 M to 0.05 M calcium chloride. Above 0.05 M calcium chloride, the tensile strength decreased.
Data are shown as mean values ± SD.

The observed increase in clot tensile strength when calcium chloride was added to
the fibrinogen concentrate was probably due to the calcium-dependent effect of factor
XIII. The concentration of factor XIII in the 15 mg/mL protamine-fibrinogen concentrate
was approximately 20 μg/mL. It has been shown that factor XIII requires calcium as a
cofactor to crosslink fibrin [6] and increases tensile strength [26-28]. There was no
calcium present in the fibrinogen concentrate before adding calcium chloride, so the
cofactor required for factor XIII to function was not available. After calcium chloride
was added, factor XIII had the required cofactor and could function properly.
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Calcium chloride concentrations below 0.0089 M were insufficient to produce the
maximum tensile strength. At these concentrations, most of the calcium was probably
bound to the free sodium citrate in the protamine-fibrinogen concentrate. Once the
threshold of 0.0089 M was reached, enough calcium was present to bind all of the free
sodium citrate with excess to provide a cofactor for factor XIII. At calcium chloride
concentrations above 0.05 M, enough free calcium was probably present in the
protamine-fibrinogen concentrate to displace sodium citrate from protamine, resulting in
partial precipitation of the fibrinogen and reduction in the tensile strength.
To verify that the increase in tensile strength when calcium chloride was added to
the fibrinogen concentrate was due to factor XIII, the tensile strength of samples prepared
from pure fibrinogen with and without factor XIII and calcium was measured. Samples
were prepared from a 15 mg/mL pure fibrinogen concentrate with nothing added, 0.0089
M calcium chloride, 10 μg/mL factor XIII, and 10 μg/mL factor XIII with 0.0089 M
calcium chloride (Figure 5.6). The increase in tensile strength to approximately 90 kPa
when factor XIII and calcium were added together (Figure 5.6) more than explains the
effect of calcium summarized in Figure 5.5.
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Figure 5.6: Tensile strength as a function of factor XIII content and calcium content (n=4).
Fibrinogen concentration of 15 mg/mL was used. 0.0089M Calcium and 10 μg/mL factor XIII alone
did not cause an increase in tensile strength. When calcium and factor XIII were added together,
the tensile strength increased significantly over the other samples (p<0.05). Data are shown as mean
values ± SD.

The combined effect of fibrinogen concentration and calcium on tensile strength
was evaluated by preparing samples with fibrinogen concentrations of 15, 30, 45, and 60
mg/mL and a calcium chloride concentration of 0.0089 M. Controls of pooled plasma (3
mg/mL), pure fibrinogen (15 mg/mL), and Tisseel (average concentration 95 mg/mL)
were used (Figure 5.7).
At each fibrinogen concentration the addition of calcium chloride to the
protamine-fibrinogen concentrate significantly increased the tensile strength compared
with the protamine-fibrinogen concentrate without calcium (p<0.05). The tensile strength
of protamine-fibrinogen with calcium was greater than that of Tisseel even with one-half
of the fibrinogen concentration. This was probably because Tisseel does not contain any
factor XIII. No change in tensile strength was observed when calcium chloride was
40

added to pure fibrinogen, which was expected because pure fibrinogen contained no
factor XIII.
No change in tensile strength was also observed when calcium chloride was added
to citrated plasma. This may have been because free calcium was already present in the
citrated plasma even when no calcium chloride was added. This would have led to factor
XIII activity in both cases of no calcium chloride and with calcium chloride. This
observation may also have been due to the low factor XIII concentration in plasma. The
plasma concentration of factor XIII is 10 μg/mL [3] while the factor XIII concentration in
15, 30, 45, and 60 mg/mL protamine-fibrinogen concentrates was approximately 20, 50,
70, and 95 μg/mL
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Figure 5.7: Tensile strength as a function of fibrinogen concentration with (0.0089 M) and without
calcium chloride (n=4). Controls of plasma, plasma with 0.0089 M calcium, pure fibrinogen, and
Tisseel were used. Adding calcium significantly increased the tensile strength as compared to pure
fibrinogen, Tisseel, and fibrinogen without calcium (p<0.05). Data are shown as mean values ± SD.
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5.1.5

Effect of Cure Time
The effect of cure time on the tensile strength was evaluated by casting clots in

the molds and allowing them to cure for 1, 5, 10, 15, 30, and 60 minutes. Samples were
prepared from a 15 mg/mL fibrinogen concentrate with 0.0089 M calcium chloride and
without calcium chloride.
Clots prepared from fibrinogen to which calcium was added reached a maximum
tensile strength in 1 minute (Figure 5.8). It is possible that the cure time required for
clots with calcium is less than 1 minute, however the shortest cure time that could be
measured was 1 minute. Clots prepared without calcium chloride reached a maximum
tensile strength in about 5 minutes.
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Figure 5.8: Tensile strength as a function of cure time with (0.0089 M) and without calcium chloride
(n=4). Fibrinogen concentration was 15 mg/mL. Sealant was kept at 37oC and samples were cured
at 22oC. Samples containing calcium chloride reached a maximum tensile strength in 1 minute or
less. Samples without calcium chloride required 5 minutes to reach the maximum strength. Data are
shown as mean values ± SD.
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5.1.6

Effect of Aprotinin and ε-Aminocaproic Acid
The effect of the presence of fibrinolytic inhibitors on tensile strength was

investigated. Samples were prepared from a 15 mg/mL fibrinogen concentrate with
0.0089 M calcium chloride and without calcium chloride. Aprotinin (Trasylol Injection,
Bayer Corp., West Haven, CT) was added to the fibrinogen concentrate to bring the total
concentration to 3000 KIU (Kallikrein Inhibitor Units)/mL. ε-Aminocaproic (Sigma
Chemical Co.) was added to the fibrinogen concentrate separate from aprtotinin to bring
the total concentration to 10 mg/mL. There were no significant changes in tensile
strength upon addition of the antifibrinolytic agents (Figure 5.9).

Figure 5.9: Tensile strength of samples prepared with antifibrinolytic agents with (0.0089M) and
without calcium chloride (n=4). Fibrinogen concentration of 15 mg/mL was used. Antifibrinolytic
agents used were aprotinin and epsilon-aminocaproic acid (eACA). No significant differences in
tensile strength were observed when the antifibrinolytic agenets were added. Data are shown as
mean values ± SD.
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5.2

Adhesion Strength

5.2.1

Experimental Method
Samples for adhesion strength testing were prepared by sealing together two

pieces of vascular tissue and then pulling them apart, simulating how a sealant would
perform when applied to cut tissue. Bovine aorta was obtained from a local abattoir and
was prepared in four steps as shown in Figure 5.10. First, a lengthwise incision was
made through the aorta wall and the aorta was laid flat. The aorta was then cut into
smaller strips. Each strip was approximately 3 cm long and 1 cm wide. Because clots
would not adhere to the endothelial lining of the intima, it was necessary to split each
strip down the length of the wall. Each strip was cut down the length of the wall between
the adventitia and intima, yielding a strip with media on one side and intima on the other
and a strip with media on one side and adventitia on the other. Sealant was applied (0.1
mL), covering an approximate area of 1cm2, between the medial linings of the aorta strips
and a 100 g weight was placed on top of the overlapping joint. The exact area of the
overlapping joint was carefully measured with a digital caliper. The samples were
allowed to cure for 30 minutes and then placed in an Instron Model 1120 Universal
Testing Instrument (max load 500 g). Stress-strain was recorded while the sample was
strained at 100 mm/min until the overlapping joint failed. Adhesion strength was taken
as the maximum stress sustained.
The adhesion model provided a good simulation of sealant being applied to cut
tissue. The model did not provide a good simulation of fibrin sealant being applied to
sutured vascular tissue or skin.
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Figure 5.10: Steps in preparing samples for adhesion strength testing. Step 1) the aorta was sliced
lengthwise and laid open. Step 2) the aorta was cut into strips. Step 3) each strip was split down the
media to give two strips of aorta. Step 4) sealant was applied to the media and the strips were
overlapped.

5.2.2

Effect of Thrombin
The effect of the amount of thrombin on adhesion strength was determined by

keeping the fibrinogen concentration constant and changing the amount of thrombin used.
Sealant was prepared as previously described (see Chapter 4). Samples were prepared
from a 15 mg/mL fibrinogen concentrate and 75, 100, or 125 U of bovine thrombin (final
concentrations 45, 60, 75 U/mL clot). No significant differences (p=0.74) were observed
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between the adhesion strengths from the three different amounts of thrombin (Figure
5.11). The rest of the adhesion strength experiments were performed with a final
thrombin concentration of 60 U/ml clot.
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Figure 5.11: Adhesion strength as a function of final thrombin concentration in the clot (n=8).
Fibrinogen concentration was 15 mg/mL. No significant differences (p=0.74) were observed at the
different thrombin concentrations. Data are shown as mean values ± SD.

5.2.3

Effect of Fibrinogen Concentration
To evaluate the effect of fibrinogen concentration on adhesion strength, samples

were prepared with fibrinogen concentrations of 15, 30, 45, and 60 mg/mL. Controls of
pooled plasma (3 mg/mL), pure fibrinogen (15 mg/mL), and Tisseel (average
concentration 95 mg/mL) were used. Adhesion strength was found to increase
approximately linearly with increasing fibrinogen concentration (Figure 5.12).
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Figure 5.12: Adhesion strength as a function of fibrinogen concentration (n=8). Controls of plasma,
pure fibrinogen, and Tisseel were used. The adhesion strength increased linearly with fibrinogen
concentration. The adhesion strength of plasma falls near the curve. The adhesion strength of
Tisseel fell below the curve. The adhesion strength of pure fibrinogen was significantly larger than
the protamine-fibrinogen (p<0.05). Data are shown as mean values ± SD.

The adhesion strength of the sample formed with plasma falls near the curve with
the samples formed from protamine-fibrinogen concentrate. The adhesion strength of
Tisseel is much lower than what is suggested by its fibrinogen concentration. This
observation may be evidence that protamine not only precipitates fibrinogen and factor
XIII, but also precipitates adhesive proteins as well. The concentrations of these
adhesive proteins may be higher in the protamine-fibrinogen concentrate than in Tisseel.
The tensile strength of the 15 mg/mL pure fibrinogen sample is significantly greater than
the 15 mg/mL protamine-fibrinogen sample (p<0.05). The presence of protamine in the
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fibrinogen concentrate lowers the adhesion strength of a clot formed as compared to a
clot formed with concentrated pure fibrinogen.

5.2.4

Effect of Calcium
The effect of calcium on adhesion strength was investigated by adding calcium

chloride to a 15 mg/mL solution of protamine-fibrinogen. Final concentrations of
calcium chloride in the fibrinogen concentrate were 0, 0.0018, 0.0036, 0.0089, 0.018,
0.035, 0.05, 0.075, and 0.1 M. The concentration of calcium chloride in the concentrate
yielding the highest adhesion strength was in the range of 0.0036 to 0.1 M (Figure 5.13).
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Figure 5.13: Adhesion strength as a function of calcium chloride concentration (n=8). A fibrinogen
concentration of 15 mg/mL was used. The adhesion strength reached a maximum in the range of
0.0036 M to 0.1 M calcium chloride. Data are shown as mean values ± SD.
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The observed increase in adhesion strength when calcium chloride was added to
the fibrinogen concentrate was due to the calcium-dependent effect of factor XIII. It has
been shown that factor XIII requires calcium as a cofactor to crosslink fibrin and
adhesive proteins and increase adhesion strength [29-31]. There was no calcium present
in the fibrinogen concentrate before adding calcium chloride, so the cofactor required for
factor XIII to function was not available. After calcium chloride was added, factor XIII
had the required cofactor and could function properly.
Calcium chloride concentrations below 0.0036 M were insufficient to produce the
maximum adhesion strength. Unlike tensile strength, the maximum adhesion strength
remained constant over the range of calcium chloride concentrations once the threshold
of 0.00036 M was reached. Tensile strength is a strong function of fibrinogen
concentration, while adhesion strength is a function of not only fibrinogen, but adhesive
proteins as well. Calcium chloride concentrations above 0.05 M may precipitate enough
fibrinogen to affect the tensile strength, but may not be enough to affect the adhesion
strength due to the significant influence of adhesive proteins.
The combined effect of fibrinogen concentration and factor XIII on adhesion
strength was evaluated by preparing samples with fibrinogen concentrations of 15, 30,
45, and 60 mg/mL and calcium chloride concentration of 0.0089 M. Controls of pooled
plasma (3 mg/mL), pure fibrinogen (15 mg/mL), and Tisseel (average concentration 95
mg/mL) were used (Figure 5.14).
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Figure 5.14: Adhesion strength as a function of fibrinogen concentration with (0.0089 M) and
without calcium chloride (n=8). Controls of plasma, pure fibrinogen, and Tisseel were used. Adding
calcium significantly increased the adhesion strength as compared to Tisseel and fibrinogen without
calcium (p<0.05). No significant difference was observed for pure fibrinogen. Data are shown as
mean values ± SD.

At each fibrinogen concentration the addition of calcium chloride to the
protamine-fibrinogen concentrate significantly increased the adhesion strength compared
with the protamine-fibrinogen concentrate without calcium (p<0.05). No change in
adhesion strength was observed when calcium chloride was added to pure fibrinogen,
probably because there was no factor XIII present in the pure fibrinogen concentrate. No
change in adhesion strength was also observed when calcium chloride was added to
citrated plasma. This may have been because free calcium was already present in the
citrated plasma even when no calcium chloride was added. This would have led to factor
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XIII activity in both cases of no calcium chloride and with calcium chloride. This
observation may also have been due to the low factor XIII concentration in plasma. The
adhesion strength of Tisseel was found to be significantly less than that of clots formed
with 30, 45 and 60 mg/mL protamine-fibrinogen concentrates with 0.0089 M calcium
chloride (p<0.05).

5.2.5

Effect of Cure Time
The effect of cure time on adhesion strength was evaluated by preparing samples

and allowing them to cure for 1, 5, 10, 15, 30, and 60 minutes. Samples were prepared
from a 15 mg/mL fibrinogen concentrate with 0.0089 M calcium chloride and without
calcium chloride (Figure 5.15). Clots prepared from fibrinogen to which calcium was
added reached a maximum adhesion strength in 15 minutes. Clots prepared without
calcium chloride reached a maximum adhesion strength in about 5 minutes.
The time required to reach the maximum tensile strength is much lower than the
time required to reach the maximum adhesion strength. This provides evidence that the
kinetics of fibrin polymerization, which the cure time for tensile strength is dependent on,
are much faster than the kinetics of bond formation between the fibrin network and the
adhesive proteins.
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Figure 5.15: Adhesion strength as a function of cure time with (0.0089 M) and without calcium
chloride (n=8). Fibrinogen concentration was 15 mg/mL. Sealant was kept at 37oC and samples
were cured at 22oC. Samples containing calcium chloride reached a maximum tensile strength at 5
minutes. Samples without calcium chloride required 5 minutes to reach the maximum strength.
Data are shown as mean values ± SD.

5.2.6

Effect of Aprotinin and ε-Aminocaproic Acid
The effect of the presence of fibrinolytic inhibitors on adhesion strength was

investigated. Samples were prepared from a 15 mg/mL fibrinogen concentrate with
0.0089 M calcium chloride and without calcium chloride. Aprotinin was added to the
fibrinogen concentrate to bring the total concentration to 3000 KIU/mL. ε-Aminocaproic
was added to the fibrinogen concentrate separate from aprotinin to bring the total
concentration to 10 mg/mL. There were no significant changes in adhesion strength upon
addition of the antifibrinolytic agents (Figure 5.16).
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Figure 5.16: Adhesion strength of samples prepared with antifibrinolytic agents with (0.0089M) and
without calcium chloride (n=8). Fibrinogen concentration of 15 mg/mL was used. Antifibrinolytic
agents used were aprotinin and epsilon-aminocaproic acid (eACA). No significant differences in
Adhesion strength were observed when the antifibrinolytic agents were added. Data are shown as
mean values ± SD.

5.3

Donor Variation

A major criticism of conventional autologous fibrin sealants is the poor
reproducibility of their mechanical properties and clinical performance [79]. Plasma
fibrinogen levels vary considerably between individuals, being affected by age, sex, race,
alcohol intake, and smoking, as well as certain disease states. Fibrinogen concentrations
of 2-6 mg/mL are typical of patients undergoing surgery [86-89]. These variations in
fibrinogen concentration are manifested as variations in concentration of fibrin sealants
prepared from autologous donations, which leads to poor reproducibility [49, 90].
The effect of donor variation on the mechanical properties of the protamineprecipitated fibrinogen concentrate was evaluated. Blood was drawn into sodium citrate
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(final concentration 3.8 gm/100 mL) from 10 donors, 5 male and 5 female. The
fibrinogen concentration in the plasma was measured with the Clauss method [91].
Diluted fibrinogen was clotted in the presence of excess thrombin in a CoaData 2000
Fibrintimer (Labor GmbH, Hamburg, Germany). The clotting time was recorded and the
fibrinogen concentration was calculated from a standard curve. The fibrinogen was
precipitated with protamine as described and concentrated to 15 mg/mL without the
addition of calcium. The adhesion and tensile strengths were measured as previously
described and were compared to fibrinogen concentrate from pooled donor plasma
(Figure 5.17).
The adhesion and tensile strengths of the individual donors were not significantly
different from the pooled plasma values. One donor had a high plasma fibrinogen
concentration (4 mg/mL), reflected in the increased adhesion and tensile strengths over
the other samples. Because the mechanical properties are dependent on the fibrinogen
concentration, an autologous sealant made from a patient with an abnormally low
fibrinogen concentration (<2 mg/mL) will have mechanical properties significantly lower
than the pooled plasma values.

54

Figure 5.17: Tensile strength (n=4) and adhesion strength (n=8) as a function of individual
fibrinogen concentration. Fibrinogen concentration of 15 mg/mL without calcium was used. The
tensile and adhesion strengths of the donors were not different from the pooled plasma (except for
the outlier). Data are shown as mean values ± SD.
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CHAPTER 6: KINETICS

While tensile strength and adhesion strength are good indicators of how well a
fibrin sealant will perform, the most important parameter for hemostasis is the speed of
clotting, which is a function of thrombin concentration and fibrinogen concentration [24].

6.1

Experimental Methods

The kinetics of the thrombin-fibrinogen interaction in the fibrin sealant were
determined by measuring the clotting curve [22, 92, 93]. The clotting curve was
measured as an increase in absorbance at 420 nm as a function of time using a Beckman
Coulter DU 640 spectrophotometer (Beckman Coulter, Inc, Fullerton, CA). 0.5 mL of
fibrinogen concentrate was put into a cuvette and placed in the spectrophotometer. 50 μL
of bovine thrombin was injected into the cuvette to start the reaction and the absorbance
was monitored continuously up to 180 seconds. To confirm that the thrombin and
fibrinogen were completely mixed, samples were also prepared by injecting the sealant
into a cuvette using a Duploject. No differences between the clotting curves for the two
methods of sample preparation were observed. It was assumed that both techniques
provided complete mixing.
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A sample clotting curve is shown in Figure 6.1. Initially there is a time interval
during which the optical density remains close to zero. This time interval is associated
with the enzymatic events involved before clot formation [94]. The optical density then
increases in a sigmoid shape. As fibrin monomers polymerize, the optical density
increases with time [94]. The slope at the inflection is extrapolated to zero to give the
predicted time required for the thrombin to convert the fibrinogen into fibrin monomer, or
the clotting time. The slope at the inflection represents the rate of the hypothetical
polymerization reactions involved in clot formation [92].
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Figure 6.1: A sample clotting curve. The clotting time was calculated by extrapolating the slope at
the inflection to an optical density of zero. The clotting time represents the enzymatic cleavage of
fibrinogen to fibrin by thrombin. The slope through the inflection represents the rate of the
polymerization steps in clot formation.
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6.2

Effect of Thrombin Concentration

The effect of thrombin concentration on clotting time was determined by
measuring the clotting curves at thrombin concentrations of 10, 25, 50, 100, 200, 300,
400, and 500 U/mL and a fibrinogen concentration of 15 mg/mL with no calcium. The
clotting time decreased as the thrombin concentration increased (Figure 6.2). At a
thrombin concentration of 10 U/mL, the time required for the fibrinogen to be converted
to fibrin was 57.6 seconds. When the thrombin concentration was increased to 500 U/mL
the clotting time decreased to 2.5 seconds.
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Figure 6.2: Clotting time as a function of thrombin concentration (n=2). Fibrinogen concentration
of 15 mg/mL was used. The clotting time decreased as the thrombin concentration increased. Data
are shown as mean values ± SD.
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6.3

Effect of Fibrinogen Concentration

The effect of fibrinogen concentration on clotting time was determined by
measuring the clotting curves at fibrinogen concentrations of 30, 15, 9, 6, 3.75, 2, and 1
mg/mL and a thrombin concentration of 100 U/mL with no calcium. The clotting time
decreased as the fibrinogen concentration increased (Figure 6.3). The clotting time at a
fibrinogen concentration of 1 mg/mL was 28.1 seconds. When the fibrinogen
concentration was increased to 6 mg/mL the clotting time decreased to 8.4 seconds. At
fibrinogen concentrations above 6 mg/mL no change in the clotting time was observed
with increasing fibrinogen concentration. The enzymatic reaction at this point was no
longer limited by the amount of fibrinogen, but by the amount of thrombin. As shown
previously, increasing the thrombin concentration to 500 U/mL decreased the clotting
time of the 15 mg/mL fibrinogen to 2.5 seconds.
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Figure 6.3: Clotting time as a function of fibrinogen concentration (n=2). Thrombin concentration of
100 U/mL was used. The clotting time decreased as fibrinogen concentration increased. Data are
shown as mean values ± SD.

6.4

Kinetic Parameters

The enzymatic reaction between thrombin and fibrinogen can be described with
Michaelis-Menton enzyme kinetics [95]. The fibrinogen concentration and thrombin
concentration data were fit with the Mechaelis-Menton equation (Equation 6.1):

− rA =

k cat C E C A
KM + CA

(6.1)

where CE is the enzyme concentration, CA is the substrate concentration, KM is the
apparent equilibrium constant for the dissociation of the enzyme-substrate complex, and
kcat is the rate constant for the formation of product from the enzyme-substrate complex.
Values for KM and kcat are reported in Table 6.1 using thrombin as the enzyme and
fibrinogen as the substrate for clots prepared from protamine-fibrinogen concentrate and
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previously published values for clots prepared from pure fibrinogen. The fit constants
agree favorably with previously published values showing that protamine does not
adversely affect the kinetics of clotting.

Table 6.1: Kinetic constants for the Michaelis-Menton equation.

This work

Mihalyi [96]

Martinelli & Scheraga
[97]

KM (x105) (mol/L)

1.8 ± 0.4

0.6

1.13

kcat (min-1)

0.45 ± 0.1

0.101

0.033

6.5

Operating Conditions

Clotting times were measured for sealants prepared with fibrinogen
concentrations of 15, 30, and 45 mg/mL with and without calcium and a thrombin
concentration of 500 U/ml (Figure 6.4).
The addition of calcium to the fibrin sealant did not change the kinetic behavior at
the different fibrinogen concentrations. The addition of calcium to the fibrin sealant
decreased the clotting time on average 0.18 seconds. The addition of calcium did change
the mechanical properties of the sealant, as has been shown, and should be included in
the final preparation. The clots formed from the sealant polymerized very rapidly as
well. All preparations were completely polymerized at 20 seconds.
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Figure 6.4: Clotting time for fibrinogen concentrations of 15, 30, and 45 mg/mL with (0.0089 M)
calcium and without (n=2). Thrombin concentration of 500 U/mL was used. The mean clotting times
for all of the preparations were 2.5 seconds or less. Adding the calcium reduced the clotting times on
average by 0.18 seconds. Samples were completely polymerized within 15 seconds. Data are shown
as mean values ± SD.

6.6

Commercial Product

The clotting curve for Tisseel was measured and compared to fibrin sealant with a
fibrinogen concentration of 95 mg/mL (average fibrinogen concentration in Tisseel) and
a thrombin concentration of 500 U/mL (Figure 6.5). Samples were prepared by injecting
the sealant into a cuvette using a Duploject.
The shapes of the clotting curves for Tisseel and the sealant prepared from 95
mg/mL protamine-fibrinogen were the same. Both sealants clotted so rapidly that the
clotting time could not be measured. The polymerization of both sealants was also very
rapid.
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Figure 6.5: Absorbance at 420 nm as a function of time for a 95 mg/mL fibrinogen concentrate (n=2)
and Tisseel (n=1). The sealant prepared from the protamine-fibrinogen concentrate and Tisseel
exhibit similar kinetics. Data are shown as mean values ± SD.
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CHAPTER 7: ANIMAL MODEL

7.1

Experimental Methods

Adult male Wistar rats (Rattus rattus) (250-400 gm) were anesthetized by an
intraperitoneal injection (0.1 mL/100 g) of a cocktail of xylazine (10 mg/kg) (Butler Co.,
Columbus, OH) and ketamine (90 mg/kg) (Fort Dodge Labs, Fort Dodge, IA). Breathing
rate and depth and response to a toe or tail pinch were monitored throughout the
procedure to ensure proper anesthesia.
Laparotomy was performed to open the abdominal cavity and expose the kidneys.
The abdominal cavity was dried with gauze to minimize accumulated body fluids
immediately before making a 1.00 cm long, 0.5 cm deep incision in the kidneys using a
scalpel cutting guide. The scalpel cutting guide provided a way to make a repeatable
incision of 1.00 ± 0.05 cm long and 0.5 ± 0.01 cm deep. The wound was then allowed to
bleed for 5 seconds, wiped clean, and 0.3 ml of fibrin sealant was applied to the wound
with a Duploject. This procedure was repeated in the opposite kidney with a control
sealant. The order in which the sealant and controls were applied was randomized as was
the kidney used.
Blood loss was measured by absorbing blood around the wound site, without
touching the wound or sealant, with pre-weighed gauze and weighing the gauze after the
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blood was absorbed. The gauze was stored in small sealed bags between blood
absorption and weighing to minimize evaporation. This was repeated until blood no
longer stained a clean piece of gauze. Bleeding time was measured by starting a timer
when the fibrin sealant was applied and stopping the timer when blood no longer stained
a clean piece of gauze. Blood samples were collected for hematology and aggregometry
analysis at the end of the experiments via cardiac puncture while the animal was under
anesthesia.
The animals were euthanized at the end of each experiment due to the severe
damage done to the kidneys. Humane euthanasia was enacted by cardiac injection of
pentobarbital (200 mg/kg) (Fort Dodge Animal Health, Fort Dodge, IA) while the animal
was still under anesthesia. Death was determined by respiratory and cardiac arrest.

7.2

Experimental Results

7.2.1

Hematology and Aggregometry
Complete blood counts were performed at the Utah Artificial Heart Institute on

blood samples collected from the animals. The results shown in Table 7.1 are consistent
with published data for Wistar rats [98].
Aggregometry was performed to verify that the anesthetics were not adversely
affecting platelet functionality. 500 μL of PRP were aggregated with 50 μL of adenosine
diphosphate (Sigma Chemical Co.; stock concentration 1 mM). Aggregation was
measured in a Chronolog 560-ca Dual Sample Aggregometer (Chronolog Corp.,
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Havertown, PA). Maximum platelet aggregation was 65% ± 21%, which agrees with the
published value of 68% ± 30% [98].

Table 7.1: Hematology of Wistar rats. Data are shown as mean values ± SD.

This Work

Lewis, et al.

Red Blood Cells (x106/μL)

6.6 ± 0.5

5.9 ± 0.4

White Blood Cells (1/μL)

5.1 ± 2.4

5.4 ± 1.9

Hematocrit (%)

41.0 ± 3.0

---

Hemoglobin (g/dL)

14.2 ± 0.8

13.0 ± 0.7

Platelets (x103/μL)

800 ± 155

1109 ± 310

7.2.2

Sealant Performance
Blood loss and bleeding time were evaluated for sealants prepared from 15, 30,

45, and 60 mg/mL fibrinogen concentrates with 0.0089 M calcium chloride and without
calcium chloride. Control sealants used were pooled plasma, 50 U thrombin in 0.2 mL
sodium citrate, and Tisseel. A control where nothing was applied to the wound was also
used.
All of the fibrin sealant preparations significantly reduced the blood loss and
bleeding time over the controls (p<0.05) (Figure 7.1). For sealant preparations with
added calcium, no significant differences were observed between the different fibrinogen
concentrations. The only significant difference between sealants with and without
calcium was at a fibrinogen concentration of 15 mg/mL.
Blood loss and bleeding time for Tisseel were significantly greater than the results
for 30, 45, and 60 mg/mL fibrinogen concentrates with calcium chloride and 60 mg/mL
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fibrinogen concentrate without calcium chloride (p<0.05). This observation is attributed
to the low adhesion strength of Tisseel.

Figure 7.1: Bleeding time and blood loss as a function of fibrinogen concentration (n=5). Controls
used were nothing, plasma, thrombin, and Tisseel. All sealant preparations significantly decreased
the blood loss and bleeding time over the controls of plasma, thrombin, and nothing (p<0.05). 30, 45,
and 60 mg/mL fibrinogen concentrates with calcium and 60 mg/mL fibrinogen concentrate without
calcium significantly lowered blood loss and bleeding time over Tisseel (p<0.05). Data are shown as
mean values ± SD.
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7.2.3

Anticoagulated Rats
Fibrin sealants are often used in patients undergoing surgery that requires

anticoagulation (e.g. open-heart surgery requiring cardiopulmonary bypass). Heparin is
the most widely used anticoagulant in such surgery, and a heparin concentration of 2-3
U/mL in the blood provides adequate anticoagulation for that application [85].
The performance of fibrin sealant made from protamine-fibrinogen concentrate
was evaluated by measuring blood loss and bleeding time in heparinized rats. The
surgical procedure already described was followed. A bolus injection of heparin (100
U/mL) was given in the vena cava following laparotomy to bring the concentration in the
blood to 2-3 U/mL. Sealant was prepared from 30 and 60 mg/mL fibrinogen
concentrates with a calcium chloride concentration of 0.0089 M. A control sealant of
pooled plasma and a control where nothing was applied to the wound were used.
Both fibrin sealant preparations significantly lowered the blood loss and bleeding
time over the controls (p<0.05) (Figure 7.2). The blood loss and bleeding time at both
fibrinogen concentrations were significantly greater in the heparinized rat than in the nonheparinized rat (p<0.05).
The increase in blood loss and clotting time in the heparinized rat compared with
the non-heparinized rat is evidence that the animal’s native coagulation system
contributes in reducing blood loss and bleeding time. Application of the fibrin sealant in
a non-heparinized rat initiates clotting of the animal’s blood at the wound site. The fibrin
sealant and clotting of the native blood combine to help reduce the blood loss and
bleeding time. Normal clotting function in a heparinized rat is inhibited and doesn’t aid
in stopping bleeding, as observed by an increase in blood loss and clotting time.
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Figure 7.2: Blood loss and time to stop bleeding in heparinized rats (n=5). Sealants prepared from 30
and 60 mg/mL fibrinogen concentrated with 0.0089 M calcium were used. Controls of nothing and
plasma were used. The sealants significantly lowered blood loss and bleeding time in the heparinized
rats over the controls (p<0.05). Blood loss and bleeding time were greater in the heparinized rat than
in the non-heparinized rat. Data are shown as mean values ± SD.
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7.3

Mathematical Model of Animal Wound

The rat kidney wound was modeled mathematically in order to determine the
influence of the individual mechanical properties on the efficacy of the sealant. A force
balance was performed on the incision and the sealant applied to it (Figure 7.3).

Figure 7.3: Force balance on kidney incision in the animal model.

In order for the fibrin sealant to stop the wound from bleeding, the adhesive force
and tensile force of the sealant must be greater than the force exerted by the blood exiting
the wound as shown in Equations 7.1 and 7.2:

FB ≤ FT

(7.1)

FB ≤ FA

(7.2)

where FB is the force of the blood exiting the wound, FT is the tensile force of the sealant,
B

and FA is the adhesion force. These forces were calculated as shown in Equations 7.3,
7.4, and 7.5:
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FB = AI PB

(7.3)

FT = σAI

(7.4)

FA = τ ( AS − AI )

(7.5)

where AI is the cross-sectional area of the incision, PB is the blood pressure in the kidney,
B

σ is the tensile strength (see Chapter 5), τ is the adhesion strength (see Chapter 5), and AS
is the total surface area of the sealant cap. If one of the mechanical forces of the sealant
is less than force of the blood, then the sealant will not stop the wound from bleeding.

7.3.1

Model Development
The force of the blood exiting the wound was calculated as the blood pressure in

the kidney multiplied by the cross-sectional area of the incision. The mean arterial
pressure in a male Wistar rat, which is assumed to be the same in the renal artery, is
approximately 100 mmHg [99]. Ketamine/xylazine anesthetic used in rats has been
shown to lower the mean arterial pressure by 10 mmHg [100, 101]. Hence, the mean
pressure in the renal artery is estimated to be 90 mmHg. The pressure in the interlobar,
arcuate, and interlobular arteries is the same as in the renal artery [3]. Based on the size
of the incision made relative to the size of the kidney, it was assumed that the interlobar,
arcuate, and interlobular arteries were cut, and the pressure of the blood exiting the
wound was assumed to be 90 mmHg. The incision was l cm long and 1 mm wide at the
surface of the kidney yielding a cross-sectional area of 10 mm2 and a force of blood
exiting the wound of 0.12 N.
The force that sealant can hold is a combination of the tensile force and the
adhesive force. The sealant has to have a strong enough tensile force to prevent the blood
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from rupturing the clot and a strong enough adhesive force to adhere to the kidney and
anchor the clot. The tensile and adhesion forces were calculated from the time-dependent
curves shown previously (see Chapter 5). The adhesive force was calculated from the
adhesive strength and the surface area of the kidney covered by the applied sealant. The
sealant was assumed to form a circular disc with a diameter of 1.1 cm and surface area of
0.95 cm2. A lower surface area than was actually measured was assumed to account for
the formation of blood leak channels under the sealant. The cross-sectional area of the
incision was subtracted from the surface area of the sealant disc to give the total surface
area of the sealant contacting the kidney tissue. The tensile force was calculated from the
cross-sectional area of the incision and the tensile strength.

7.3.2

Results
The bleeding time was predicted for the conditions described using fibrin sealant

with fibrinogen concentrations of 15, 30, 45, and 60 mg/mL, thrombin concentration of
500 U/mL, and with and without calcium chloride. The predicted bleeding time was
calculated as the time required for the tensile and adhesion forces to reach the same force
exerted by the blood coming out of the wound. The greater of the two times for the
tensile and adhesion force development determined the bleeding time. The calculated
bleeding times were compared to the experimental values (Figure 7.4). For the sealant
containing calcium, the predicted values matched the experimental values within an
average of 6 seconds with a maximum difference of 10 seconds. The predicted values for
sealant without calcium matched the experimental values within an average of 22 seconds
with a maximum difference of 50 seconds.
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Figure 7.4: Predicted and experimental (n=5) bleeding times. The predicted bleeding times for
sealants with calcium match the experimental results within an average of 6 seconds. The predicted
bleeding times for sealants without calcium match the experimental results within an average of 22
seconds. Experimental results are shown as mean values ± SD.

The bleeding time calculated from the adhesion force at each sealant formulation
was much greater than the bleeding time calculated from the tensile force (Figure 7.5).
The time required for the tensile strength to reach its maximum strength is not only much
shorter than the time required for the adhesion strength, but the magnitude of the
maximum tensile strength is also much higher than adhesion strength (see Chapter 5).
These factors contribute to the differences in the predicted bleeding times calculated for
adhesion and tensile. As was shown in the animal model, the presence of calcium
reduces the bleeding time.
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Figure 7.5: Time curves of adhesion force and tensile force as a function of time compared to the
force exerted by the blood exiting the wound. Sealants preparations with 15, 30, 45, and 60 mg/mL
fibrinogen concentrations with (0.0089 M) and without calcium chloride were modeled. The bleeding
time for all sealant preparations was limited by the adhesion force.

The effect of changing the force of the exiting blood on bleeding time was
investigated by predicting the bleeding time for wounds with blood pressures in the range
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of 0 to 100 mmHg. Calculations were made for a sealant with a fibrinogen concentration
of 15 mg/mL with and without calcium (Figure 7.6).
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Figure 7.6: Predicted bleeding time as a function of blood pressure in the wound. A sealant prepared
from 15 mg/mL fibrinogen concentrate with (0.0089 M) and without calcium chloride was modeled.
The bleeding time decreased as the pressure in the wound decreased. The sealant with calcium had
lower bleeding times at all pressures than the sealant without calcium.

The predicted bleeding times in sealants with and without calcium decreased as
the blood pressure in the wound decreased. At lower blood pressures, the force exerted
by the exiting blood was lower, which resulted in a lower adhesion force required to stop
bleeding. The sealant can stop a low-blood-pressure wound from bleeding faster than it
can stop a high-blood-pressure wound.
The effect of changing the surface area of adhesion on the predicted bleeding time
was investigated. Bleeding times were predicted for surface areas of 0.1, 0.5, 1, and 2
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cm2 and a blood pressure of 90 mmHg. Calculations were made for a sealant with a
fibrinogen concentration of 15 mg/mL with and without calcium (Figure 7.7).
The bleeding time increased as the adhesion surface area decreased. The surface
area required to stop bleeding was 0.5 cm2 or greater in both sealant preparations. A
surface area of 0.1 cm2 was too low for both preparations of fibrin sealant to stop the
wound from bleeding.

Figure 7.7: Adhesion force as a function of time at different adhesion surface areas. Surface areas of
0.1, 0.5, 1, and 2 cm2 were predicted. Predictions were made for a 15 mg/mL fibrinogen
concentration with (0.0089 M) and without calcium chloride.

The ability of a fibrin sealant to stop a wound from bleeding is limited by the
adhesion strength of the sealant as shown with the mathematical model. It has been
shown that the adhesion strength increased with fibrinogen concentration and addition of
calcium. When sealing a high-pressure wound, a high fibrinogen concentration with
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added calcium should be used to reduce the bleeding time and blood loss. If the sealant is
to be used for sealing a low-pressure wound, a low fibrinogen concentration with added
calcium will be adequate in reducing the bleeding time and blood loss. It should also be
noted that enough fibrin sealant must be applied to cover the wound and surrounding
tissue in order to provide enough surface area for the sealant to adhere to the tissue.
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CHAPTER 8: SUMMARY AND CONCLUSIONS

This dissertation reports the in-vitro and animal experimental evaluation of a
rapid and inexpensive method to produce autologous fibrinogen concentrate for use in
fibrin sealant. Following are the new contributions to the field.

8.1

Novel Use of Protamine to Harvest Fibrinogen

For the first time, fibrinogen was harvested by precipitation with protamine
sulfate and concentrated for use in a fibrin sealant. At the optimal conditions, 96% ± 4%
of the fibrinogen present in the plasma was precipitated with protamine, and 98% ± 0.9%
of the precipitated fibrinogen was clottable. In addition, it was shown that almost 50% of
the factor XIII in the plasma was precipitated along with the fibrinogen.

8.2

More Consistent Methods to Test Tensile and Adhesion Strength

In-vitro models to evaluate tensile strength and adhesion strength were designed
and fabricated and these models provided more control than previously-published
models. This was accomplished by using precise molds with controlled location of
failure and repeatable tissue preparation which lowered the variability. Tensile strength
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and adhesion strength both increased with increasing fibrinogen concentration. Addition
of calcium chloride to the concentrate significantly increased the tensile and adhesion
strengths. When calcium was added to the concentrate, clots reached their maximum
tensile strength in less than a minute and reached their maximum adhesion strength in 5
minutes. The maximum tensile and adhesion strengths in the presence of calcium were
significantly greater than the tensile and adhesion strengths of Tisseel. The addition of
antifibrinolytic agents to the fibrinogen concentrate was shown to have no effect on the
mechanical properties of the sealant.

8.3

Kinetic Study

Kinetic experiments showed that the clotting time decreased with increased
thrombin concentration and fibrinogen concentration and that protamine did not
adversely affect the kinetics. Michaelis-Menton constants were calculated from the
fibrinogen and thrombin concentration data and agreed favorably with previously
published constants for pure fibrinogen and thrombin, showing that the protamine did not
affect the clotting kinetics. The fibrinogen concentrate was completely clotted and
polymerized in less than 20 seconds.

8.4

Relevant Animal Model

A rat model was developed to simulate a bleeding wound to evaluate the
hemostatic efficacy of a fibrin sealant made from the protamine-fibrinogen concentrate
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and the model provided more control (lower variability) than previously-published
models. This was accomplished by having a consistent, repeatable incision and a better
representation (actively-bleeding wound) of how the sealant would be used in surgery.
The fibrin sealant significantly reduced the blood loss and bleeding time when compared
to no sealant, plasma, and Tisseel. The sealant also significantly reduced blood loss and
bleeding time in rats that were anticoagulated with heparin.

8.5

Mathematical Model

For the first time, a mathematical model based on tensile strength and adhesion
strength was developed to predict the bleeding time in the animal wound. Model
predictions showed that the ability of the fibrin sealant to reduce bleeding, and therefore
blood loss, was limited by the adhesion strength. The model also showed that in order to
minimize the bleed time and blood loss, a high fibrinogen concentration (60 mg/mL) with
calcium should be used.

From the research conducted for this dissertation, it may be concluded that
autologous fibrinogen can be rapidly and inexpensively harvested with protamine sulfate.
The fibrinogen concentrate can be used in all arenas of surgery to decrease bleeding and
decrease healing time. These findings have considerable implications in trauma
situations where the need for fibrin sealant can be high and time is short.

81

82

CHAPTER 9: FUTURE DIRECTIONS

The research conducted for this dissertation suggests some potential areas of
future research. This chapter briefly outlines some of these possibilities.

9.1

Autologous Thrombin

In order for a fibrin sealant to be truly autologous, both the fibrinogen and
thrombin must be of an autologous source. Currently the thrombin component of
autologous fibrin sealant is almost always obtained from a commercially-available bovine
source. However, patient immune reaction to the bovine thrombin has been reported
[102-105]. It is estimated that 30% of all patients treated with bovine thrombin develop
antibodies to their native coagulation factors, which can lead to bleeding complications.
In addition, the possibility of viral contamination in bovine thrombin can not be ruled out,
particularly in light of recent outbreaks of mad cow disease. Commercial preparations of
human thrombin are becoming more widely used but carry the risk of virus transmission.
A rapid and inexpensive method to harvest and concentrate autologous thrombin
would reduce patient exposure to bovine thrombin and any associated coagulopathies.
Autologous thrombin could be combined with the autologous fibrinogen described in this
dissertation to give a truly autologous fibrin sealant.
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9.2

Whole Blood Precipitation

The method described in this dissertation to harvest fibrinogen requires plasma to
be separated from whole blood. This can be accomplished with centrifugation,
plasmapheresis, or filtration. Directly precipitating the fibrinogen from whole blood
would eliminate this step and reduce the processing time for harvesting autologous
fibrinogen. Preliminary attempts were undertaken to precipitate fibrinogen from whole
blood with little success. When protamine was added to whole blood, aggregates
comprised of red blood cells, protamine, and fibrinogen formed, which broke up the
network of fibrinogen precipitate. This resulted in harvesting <20 % of the fibrinogen in
the plasma.
It has been shown that protamine binds to red blood cells [106-108]. The
aggregates formed when protamine was added to whole blood were probably due to
protamine binding red blood cells and fibrinogen together. If the binding sites on the red
blood cells were to be masked with a chemical agent that does not interact with
fibrinogen, it may be possible to precipitate fibrinogen from whole blood.
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